Is my portfolio
One Report to Answer all your Questions!
Zydus Lifesciences Ltd.
BSE: 532321 | NSE: ZYDUSLIFE
Mid Cap | Pharmaceuticals & Drugs
902.15
10.60 (1.19%) Cadila Healthcare informs about press release
Date: 10-12-2021Cadila Healthcare has informed that it enclosed a copy of press release dated December 10, 2021 titled ‘Zydus announces EPICS-IIITM Phase 2(b)/3 adaptive pivotal clinical trial of Saroglitazar Mg in PBC’.
The above information is a part of company’s filings submitted to BSE